MAPT and Alzheimer disease: They exhibited their marginal effect (and therefore were FDA-approved as AD drugs) only because their makers were fortunate to be able to conduct trials at the early enough stages of AD (guided by phosphorylated tau serum biomarker not available previously) when a marginal neuronal subpopulation did not yet cross the T1 threshold and could be treated preventively.